Skip to main content

Results ‘encouraging’ from phase II trial for relapsed acute myeloid leukemia

December 21, 2018

UNC Lineberger’s Joshua Zeidner, MD, reported preliminary data at the 60th American Society of Hematology Annual Meeting from a phase II clinical trial for administering a high-dose of the chemotherapy treatment cytarabine followed by an immune checkpoint inhibitor, pembrolizumab, in patients with acute myeloid leukemia that had relapsed or no longer responded to other treatment.

Former patient donates $10 million to further blood cancer research at UNC Lineberger

October 29, 2018

Etteinne “ET” and W. G. Champion “Champ” Mitchell of New Bern, North Carolina, will create a new fund supporting ground-breaking research in blood cancer at UNC Lineberger Comprehensive Cancer Center, including lymphoma, leukemia and myeloma research, in gratitude for the care Champ received and to bolster research directed at finding cures.

Researchers lay the foundation for personalized immune treatments for leukemia

August 29, 2018

In the journal Blood Advances, UNC Lineberger’s Ben Vincent, MD, Paul Armistead, MD, PhD, and their collaborators reported early findings from a new study that could aid in the development of immune-based treatments that are tailored to individual leukemia patients who are undergoing stem cell transplantation.